Skip to main content
Top
Published in: Journal of Neuro-Oncology 1/2011

01-08-2011 | Clinical Study – Patient Study

Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles

Authors: Maria Teresa Sartori, Alessandro Della Puppa, Andrea Ballin, Graziella Saggiorato, Daniela Bernardi, Andrea Padoan, Renato Scienza, Domenico d’Avella, Giuseppe Cella

Published in: Journal of Neuro-Oncology | Issue 1/2011

Login to get access

Abstract

The relationship between venous thromboembolism (VTE) and cancer is supported by several pathogenetic factors, including circulating microparticles (MP) originating from different cells and often bearing tissue factor. Since VTE often complicates the clinical course of patients with glioblastoma multiforme (GBM; WHO grade IV astrocytoma) and the role of MPs in these patients population is still not clear, this prospective study was conducted to evaluate the procoagulant activity of circulating MP (MP activity) in GBM patients. We enrolled 61 GBM patients undergoing gross-total or subtotal surgical resection followed by combined radio-chemotherapy; 20 healthy volunteers were tested as controls. Blood samples for MP activity and hemostatic profiles were obtained before and then 1 week and 1, 4, and 7 months after surgery. GBM patients had significantly higher mean MP activity levels than healthy controls before and 7 days after surgery. During the follow-up, MP activity levels became significantly lower 1 and 4 months after surgery (P = 0.007 and P = 0.018, respectively) than prior to surgery, but this decrease was only seen in the subgroup achieving complete tumor resection. MP activity levels increased in 7 (63.6%) of 11 patients who developed VTE. The different incidence of the increase in MP activity levels between patients with and without VTE was statistically significant (χ 2 = 4.93, P = 0.026; relative risk 1.38, 95% CI 1.03–1.86). GBM patients may have an increase in MP-associated procoagulant activity that could contribute to any prothrombotic states and increases the likelihood of VTE complications; this procoagulant activity drops during control of disease.
Literature
1.
go back to reference Wun T, White RH (2009) Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest 27:63–74PubMedCrossRef Wun T, White RH (2009) Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest 27:63–74PubMedCrossRef
2.
3.
go back to reference Falanga A (2009) The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Invest 27:105–115PubMedCrossRef Falanga A (2009) The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Invest 27:105–115PubMedCrossRef
4.
go back to reference Milsom C, Rak J (2007) Tissue factor and cancer. Pathophysiol Haemost Thromb 36:160–176CrossRef Milsom C, Rak J (2007) Tissue factor and cancer. Pathophysiol Haemost Thromb 36:160–176CrossRef
5.
go back to reference Zhang J, Ding J, Zhang X, Shao X, Hao Z (2005) Regulation of vascular endothelial growth factor production and angiogenesis by tissue factor in SGC-7901 gastric cancer cells. Cancer Biol Ther 4:769–772PubMedCrossRef Zhang J, Ding J, Zhang X, Shao X, Hao Z (2005) Regulation of vascular endothelial growth factor production and angiogenesis by tissue factor in SGC-7901 gastric cancer cells. Cancer Biol Ther 4:769–772PubMedCrossRef
6.
go back to reference Zwicker JI, Furie BC, Furie B (2007) Cancer-associated thrombosis. Crit Rev Oncol Hematol 62:126–136PubMedCrossRef Zwicker JI, Furie BC, Furie B (2007) Cancer-associated thrombosis. Crit Rev Oncol Hematol 62:126–136PubMedCrossRef
7.
go back to reference Aharon A, Brenner B (2009) Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 22:61–69PubMedCrossRef Aharon A, Brenner B (2009) Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 22:61–69PubMedCrossRef
8.
9.
go back to reference CBTRUS (2009) 2009–2010 CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in eighteen states in 2002–2006. Central Brain Tumor Registry of the United States, Hinsdale, IL. www.cbtrus.org CBTRUS (2009) 2009–2010 CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in eighteen states in 2002–2006. Central Brain Tumor Registry of the United States, Hinsdale, IL. www.​cbtrus.​org
10.
go back to reference Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466PubMedCrossRef Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466PubMedCrossRef
11.
go back to reference Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma. Cancer 89:640–646PubMedCrossRef Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma. Cancer 89:640–646PubMedCrossRef
12.
go back to reference Semrad JT, O’Donnel R, Wun T et al (2007) Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106:601–608PubMedCrossRef Semrad JT, O’Donnel R, Wun T et al (2007) Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106:601–608PubMedCrossRef
13.
go back to reference Franchini M, Montagnana M, Targher G, Manzato F, Lippi G (2007) Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 24:29–38PubMedCrossRef Franchini M, Montagnana M, Targher G, Manzato F, Lippi G (2007) Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 24:29–38PubMedCrossRef
14.
go back to reference Colin C, Voutsinos-Porche B, Nanni I et al (2009) High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol 118:745–754PubMedCrossRef Colin C, Voutsinos-Porche B, Nanni I et al (2009) High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol 118:745–754PubMedCrossRef
15.
go back to reference Rong Y, Belozerov VE, Tucker-Burden C et al (2009) Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein 1 transcriptional activity. Cancer Res 69:2540–2549PubMedCrossRef Rong Y, Belozerov VE, Tucker-Burden C et al (2009) Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein 1 transcriptional activity. Cancer Res 69:2540–2549PubMedCrossRef
16.
go back to reference Wells PS, Anderson DR, Bormanis J et al (1997) Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 350:1795–1798PubMedCrossRef Wells PS, Anderson DR, Bormanis J et al (1997) Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 350:1795–1798PubMedCrossRef
17.
go back to reference Wells PS, Anderson DR, Rodger M et al (2000) Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 83:416–420PubMed Wells PS, Anderson DR, Rodger M et al (2000) Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 83:416–420PubMed
18.
go back to reference Simanek R, Vormittag R, Hassler M et al (2007) Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 9:89–95PubMedCrossRef Simanek R, Vormittag R, Hassler M et al (2007) Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 9:89–95PubMedCrossRef
19.
go back to reference Rodas RA, Fenstermaker RA, McKeever PE et al (1998) Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: a preliminary report. J Neurosurg 89:200–205PubMedCrossRef Rodas RA, Fenstermaker RA, McKeever PE et al (1998) Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: a preliminary report. J Neurosurg 89:200–205PubMedCrossRef
20.
21.
go back to reference Zwicker JI, Liebman HA, Neuberg D et al (2009) Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15:6830–6840PubMedCrossRef Zwicker JI, Liebman HA, Neuberg D et al (2009) Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15:6830–6840PubMedCrossRef
22.
go back to reference Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S (2007) Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 5:520–527PubMedCrossRef Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S (2007) Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 5:520–527PubMedCrossRef
23.
go back to reference Hron G, Kollars M, Weber H et al (2007) Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 97:119–123PubMed Hron G, Kollars M, Weber H et al (2007) Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 97:119–123PubMed
24.
go back to reference Skog J, Wurdinger T, van Rijn S et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470–1476PubMedCrossRef Skog J, Wurdinger T, van Rijn S et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470–1476PubMedCrossRef
25.
go back to reference Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S (2009) Microparticle associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 7:1421–1423PubMedCrossRef Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S (2009) Microparticle associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 7:1421–1423PubMedCrossRef
26.
go back to reference Manly DA, Wang J, Glover SL et al (2010) Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 125:511–512PubMedCrossRef Manly DA, Wang J, Glover SL et al (2010) Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 125:511–512PubMedCrossRef
27.
go back to reference Khorana AA, Francis CW, Menzies KE et al (2008) Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 6:1983–1985PubMedCrossRef Khorana AA, Francis CW, Menzies KE et al (2008) Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 6:1983–1985PubMedCrossRef
Metadata
Title
Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles
Authors
Maria Teresa Sartori
Alessandro Della Puppa
Andrea Ballin
Graziella Saggiorato
Daniela Bernardi
Andrea Padoan
Renato Scienza
Domenico d’Avella
Giuseppe Cella
Publication date
01-08-2011
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 1/2011
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-010-0462-8

Other articles of this Issue 1/2011

Journal of Neuro-Oncology 1/2011 Go to the issue